GP (HK) invests $12M in CoRISMA for heart failure device rights

China Grand Pharmaceutical and Healthcare Holdings (GP (HK)) will acquire 22.2% equity in CoRISMA MCS Systems for $12 million, and obtain exclusive development, manufacturing and commercialization rights for CoRISMA's heart failure therapeutic system in Greater China and several Southeast Asian countries.

“The global innovative advanced heart failure therapeutic system introduced by the Group this time is another global innovative product in this field.”grandpharm.com

• 1 source
• grandpharm.comGP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System - Company - News Center - Grand Pharma GroupAug 6, 2021

Summarized from public sources; check the original articles before acting on it.